|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Rating Action: Moody's assigns B3 CFR to UIC Merger Sub, Inc.. Global Credit Research- 19 Jul 2017. New York, July 19, 2017-- Moody's Investors Service, today assigned a B3 Corporate Family Rating and ...
Rating Action: Moody's places Albany Molecular's ratings on review for downgrade. Global Credit Research- 07 Jun 2017. New York, June 07, 2017-- Moody's Investors Service placed the ratings of Albany Molecular ...
Stocks that moved substantially or traded heavily Tuesday: Signet Jewelers Ltd., up $1.08 to $53.95 The jewelry retailer said its recently hired chief operating officer resigned after violating company ...
Contract drug manufacturer and research company Albany Molecular Research Inc said on Tuesday it had agreed to be taken private by buyout firms Carlyle Group LP and GTCR LLC for about $922 million in cash. Clinical research organizations can prove to be lucrative investments for private equity firms.
Shares of Albany Molecular Research saw a handy gain on Tuesday after it was announced that the company signed a definitive agreement to be acquired.
Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
Categories: Yahoo FinanceGet free summary analysis Albany Molecular Research, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Albany Molecular Research, Inc. – Charles River Laboratories International, Inc., Arena Pharmaceuticals, Inc., Cambrex Corporation, Aceto Corporation, General Electric Company, Ligand Pharmaceuticals Incorporated and Array BioPharma Inc. ... Read more (Read more...)